Fundraising Fox
Protagonist Therapeutics
NASDAQ: PTGXMilpitas, US · Founded 2006 · Delaware corporation · 162 employees on LinkedIn · 8 known investors
Find your way into Protagonist Therapeutics
Sign up to find every way you can get introduced to Protagonist Therapeutics
- Your email: who you already know at Protagonist Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Protagonist Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
Founders & leadership
Board
Investors · 8
How we know: Aisling Capital's portfolio page · Not right? Tell us
How we know: Canaan Partners's portfolio page · the S-1 prospectus · a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$17.5M disclosed across 1 of 2 rounds · 2013–2015
- Undisclosed amountSeries BJun 2013
Johnson & Johnson Development Corporation (JJDC) (lead), Lilly Ventures, Starfish Ventures
Source ↗
▶$17.5MraisedJul 2015 · 9 investors · BiotechnologyRule 506(b)
- Paul F. TruexDirector
- Asish K. Xavier, Ph.D.Director
- Michael Panaccio, Ph.D.Director
- Armen Shanafelt, Ph.D.Director
- Dinesh V. Patel, PhDExecutive Officer, Director
- Harold E. Selick, Ph.D.Director
- Offering amount
- $40M
- Amount sold
- $17.5M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
Companies working in the same space as Protagonist Therapeutics.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $218.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $223.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Protagonist Therapeutics do?
- Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
- Who are Protagonist Therapeutics's investors?
- Protagonist Therapeutics's investors include Aisling Capital, Canaan Partners, JJDC, Johnson & Johnson Innovation – JJDC, Lilly Ventures, RA Capital, Starfish Ventures.
- How much funding has Protagonist Therapeutics raised?
- Protagonist Therapeutics has disclosed $17.5M raised across 1 of its 2 known rounds.
- Where is Protagonist Therapeutics headquartered?
- Protagonist Therapeutics is headquartered in Milpitas, US.